Tert-butyl 3-[2-[2-[3-(3-methyl-2,5-dioxopyrrol-1-yl)propanoylamino]ethoxy]ethoxy]propanoate | 1374666-23-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: Tert-butyl 3-[2-[2-[3-(3-methyl-2,5-dioxopyrrol-1-yl)propanoylamino]ethoxy]ethoxy]propanoate
• 英文别名: tert-butyl 3-[2-[2-[3-(3-methyl-2,5-dioxopyrrol-1-yl)propanoylamino]ethoxy]ethoxy]propanoate
• CAS: 1374666-23-5
• 化学式: C₁₉H₃₀N₂O₇
• 分子量: 398.456
• InChiKey: HIVWMESQNNORME-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  28
• 可旋转键数：
  14
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.68
• 拓扑面积：
  111
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  Tert-butyl 3-[2-[2-[3-(3-methyl-2,5-dioxopyrrol-1-yl)propanoylamino]ethoxy]ethoxy]propanoate 在 三氟乙酸 作用下， 以 二氯甲烷 、 二甲基亚砜 为溶剂， 生成
  参考文献：
  名称：

  Development of novel linkers to conjugate pharmacophores to a carrier antibody

  摘要：

  We have developed modified maleimide novel linkers with improved chemical stability that could potentially be used in conjugating various pharmacophores such as oligo nucleotides, peptides, and proteins to antibodies to afford novel biologics with well-defined therapeutic benefits and improved pharmacokinetic properties. These linkers expand the array of tools available for bioconjugation of pharmacophores to antibodies. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.05.040
• 作为产物：
  描述：

  Citraconyl-β-alanin 、 9-氨基-4,7-二氧杂壬酸叔丁酯 在 N-羟基丁二酰亚胺 、 N,N'-二异丙基碳二亚胺 作用下， 以 四氢呋喃 为溶剂， 生成 Tert-butyl 3-[2-[2-[3-(3-methyl-2,5-dioxopyrrol-1-yl)propanoylamino]ethoxy]ethoxy]propanoate
  参考文献：
  名称：

  Development of novel linkers to conjugate pharmacophores to a carrier antibody

  摘要：

  We have developed modified maleimide novel linkers with improved chemical stability that could potentially be used in conjugating various pharmacophores such as oligo nucleotides, peptides, and proteins to antibodies to afford novel biologics with well-defined therapeutic benefits and improved pharmacokinetic properties. These linkers expand the array of tools available for bioconjugation of pharmacophores to antibodies. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.05.040

文献信息

• Anti-Diabetic Compounds
  申请人：Das Tapan Kanti

  公开号：US20120282279A1

  公开（公告）日：2012-11-08

  The present invention provides a FGF21 molecule covalently attached to the combining site of an antibody via a linker, wherein the linker is covalently attached to the side chain of a linking residue within FGF21. Various uses of the compounds are provided, including methods to prevent or treat diabetes or diabetes-related conditions.
• US8722622B2
  申请人：——

  公开号：US8722622B2

  公开（公告）日：2014-05-13
• Development of novel linkers to conjugate pharmacophores to a carrier antibody
  作者：Moorthy S.S. Palanki、Abhijit Bhat、Rodney W. Lappe、Bin Liu、Bryan Oates、John Rizzo、Nebojsa Stankovic、Curt Bradshaw

  DOI：10.1016/j.bmcl.2012.05.040

  日期：2012.7

  We have developed modified maleimide novel linkers with improved chemical stability that could potentially be used in conjugating various pharmacophores such as oligo nucleotides, peptides, and proteins to antibodies to afford novel biologics with well-defined therapeutic benefits and improved pharmacokinetic properties. These linkers expand the array of tools available for bioconjugation of pharmacophores to antibodies. (C) 2012 Elsevier Ltd. All rights reserved.